Is Agios Pharmaceuticals, Inc. overvalued or undervalued?

As of 17 October 2025, the valuation grade for Agios Pharmaceuticals, Inc. has moved from very attractive to attractive, indicating a shift towards a more cautious outlook. Based on the current metrics, the company appears to be undervalued, particularly highlighted by a P/E ratio of 4, a PEG ratio of 0.01, and an EV to EBITDA of -3.81.
In comparison to its peers, Agios Pharmaceuticals has a significantly lower P/E ratio than PTC Therapeutics, Inc., which stands at 5.85, and a much lower EV to EBITDA than Supernus Pharmaceuticals, Inc., which is at 13.83. While Agios has shown strong short-term performance, with a 1-month return of 16.23% compared to the S&P 500's 0.96%, its longer-term returns have lagged, particularly over the past three years, where it returned 50.37% versus the S&P 500's 81.19%. Overall, the valuation metrics suggest that Agios Pharmaceuticals is currently undervalued relative to its peers.